S
Saby George
Researcher at Roswell Park Cancer Institute
Publications - 167
Citations - 14398
Saby George is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Nivolumab & Renal cell carcinoma. The author has an hindex of 31, co-authored 138 publications receiving 10182 citations. Previous affiliations of Saby George include Memorial Sloan Kettering Cancer Center & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
776P Phase II trial of concurrent nivolumab in urothelial bladder cancer with radiation therapy in localized/locally advanced disease for chemotherapy ineligible patients [NUTRA trial]
Ulka N. Vaishampayan,Lance K. Heilbrun,N. Vaishampayan,C. Li,D. Shi,A. Frazier,J. Maier,Brenda Dickow,M. Kuettel,Gurkamal Chatta,Saby George +10 more
Journal ArticleDOI
Pituitary Apoplexy After Initial Leuprolide Injection
TL;DR: Clinicians should be aware of this rare but known complication of le uprolide injection so that prompt diagnosis and treatment initiation are performed in patients with leuprolide-associated pituitary apoplexy.
Journal ArticleDOI
Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71]
Bernard Escudier,Padmanee Sharma,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Howard Gurney,Frede Donskov,Katriina Peltola,John Wagstaff,Thomas Gauler,Takeshi Ueda,Huanyu Zhao,Ian M. Waxman,Robert J. Motzer +19 more
TL;DR: This research presents a novel and scalable approach called “cell reprograming” that can be used to design and administer targeted therapies for specific types of cancer.
Journal ArticleDOI
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
Paul Monk,Glenn Liu,Walter M. Stadler,Susan Geyer,Ying Huang,John J. Wright,Miguel A. Villalona-Calero,James L. Wade,Russell Z. Szmulewitz,Shilpa Gupta,Amir Mortazavi,Robert Dreicer,Roberto Pili,Nancy A. Dawson,Saby George,Jorge A. Garcia +15 more
TL;DR: Tivantinib has mild toxicity and improved PFS in men with asymptomatic or minimally symptomatic mCRPC and patients treated with tivant inib had significantly better PFS vs. those treated with placebo.
Journal ArticleDOI
Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study.
Robert J. Motzer,Padmanee Sharma,Bernard Escudier,David F. McDermott,Saby George,Sandy Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Elizabeth R. Plimack,Paul Nathan,Viktor Gruenwald,Yoshihiko Tomita,Huanyu Zhao,Ian M. Waxman,Hans J. Hammers +14 more
TL;DR: A landmark analysis of OS by best response (complete/partial response; responders, stable disease [SD], and progressive disease [PD]) within 4 mo of randomization and assessed using the Kaplan–Meier method is conducted.